|
Special Report - Special Report - October 25, 2012 |
Newswise
Ustekinumab, an antibody proven to treat the skin condition psoriasis, has now shown positive results in decreasing the debilitating effects of Crohn's Disease, say researchers at the University of California San Diego School of Medicine.
The study appeared in the Oct. 18 issue of the New England Journal of Medicine.
Results from the clinical trial showed ustekinumab (Stelara) increased clinical response and remission in patients suffering from moderate-to-severe Croh...
If you are a subscriber or have purchased this article, please login to view this article in it's entirety.
The study appeared in the Oct. 18 issue of the New England Journal of Medicine.
Results from the clinical trial showed ustekinumab (Stelara) increased clinical response and remission in patients suffering from moderate-to-severe Croh...
Article Options:
Purchase Full Article - $1.50 | Subscribe Online | Current Subscribers: Login
If you are a subscriber or have purchased this article, please login to view this article in it's entirety.
Subscribers have access to articles up to one year old. Purchased articles can be accessed in your account for 30 days.



